Suspended trial tests 'Adaptive' cancer treatment strategy
NCT ID NCT06860386
Summary
This study is testing whether adjusting medication doses based on tumor response can help control advanced kidney cancer. It combines two existing drugs (pembrolizumab and axitinib) in a new way for patients who haven't had previous treatment for their metastatic cancer. The trial aims to see if this 'adaptive' approach is feasible and whether it helps patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.